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ABSTRACT 
Objective: To evaluate the clinical usefulness of Rajahpravartini vati in the management of primary 
dysmenorrhoea (Kashtartava) and changes in the quality of life of the subjects.  
Study design: A multi-centric prospective single arm observational study.  
Setting and participants: 359 subjects aged between 16 - 35 years suffering from painful 
menstruation at least for three consecutive regular menstrual cycles were included in the study. 
Intervention: Rajahpravartini Vati a classical Ayurvedic formulation was administered 250 mg b.d. 
with lukewarm water for 90 days followed by subsequent 90 days without intervention.  
Outcome measures: The management of menstrual pain assessing by 10 points Visual Analogue 
Scale and improvement in the quality of life using SF-36 (RAND) questionnaire.  
Results: The mean VAS score of pain at baseline was 6.94 ± 1.98, decreasing to 1.7 ± 2.22 at 90th day 
which further decreased and maintained to 1.24 ± 1.9 up to 180th day. Associated symptoms like 
nausea, vomiting, constipation, giddiness, breast tenderness, diarrhea, headache and fainting were 
completely relieved. The improvements of quality of life in 8 domains viz. pain, general health, 
physical functioning, social functioning, emotional wellbeing, energy/fatigue, limitation due to 
physical health and emotional problems at the end of 90th day of intervention was also significant 
(p<0.001) in comparison to baseline. No adverse event occurred during the treatment period.  
Conclusion: Rajahpravartini Vati has shown a positive role for the treatment of dysmenorrhoea and 
to improve the quality of life of the subjects. 
KEYWORDS: Primary Dysmenorrhoea; Kashtartava; Rajahpravartini Vati; Single arm - multicentric -
prospective-observational study. 
INTRODUCTION
Dysmenorrhoea is a medical condition of pain 
during menstruation but more realistic definition 
includes cases of sufficient magnitude so as to 
incapitate daily activities.[1] A pain which is of uterine 
origin and directly linked to menstruation but with no 
visible pelvic pathology is called Primary 
dysmenorrhoea. Pain reaches a maximum between 
ages of 18 and 24 years and thereafter diminishes. The 
pain is mainly felt in hypogastrium and is often 
referred to inner and front aspects of the thighs. During 
a severe attack the patient looks drawn and pale and 
may sweat; nausea and vomiting are common; there 
may be diarrhoea and rectal and bladder tenesmus.[2]  
As per Ayurvedic classics, pain occurred in the 
any part of the body due to aggravation of Vata dosha 
and the main two reasons for it are obstruction in the 
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passage (Margavarodha) or loss of body tissues 
(Dhatukshaya). In certain conditions or gynecological 
disorders (Yonivyapad) like Vataj Rajodushti, Udavarta 
or Udavartini, Antarmukhi and Suchirmukhi Yonivyapad 
pain occurred during menstruation. According to 
Maharshi Charaka, in Udavartini yonivyapad, menstrual 
blood is pushed in upward direction by the aggravated 
Apana vayu (the governing force of menstrual force) 
due to obstruction in its normal flow in Pakwashaya 
(pericolon and pelvic region). On the basis of the 
symptom ‘immediate relief of pain following discharge 
of menstrual blood’ mentioned by Charaka, it appears 
to be the nearer to primary or spasmodic 
dysmenorrhoea.[3, 4]  
Population surveys suggest a wide variation in 
prevalence rate of dysmenorrhoea from studies around 
the world including India reporting a range between 
28% and 71.7%.[5-9] It is reported in a study that 
Dysmenorrhoea is a common problem in India 
(79.67%) and most of them (37%) suffered regularly 
from dysmenorrhoea severity.[10]  
In conventional system, drug therapy includes 
Prostaglandin Synthetase Inhibitors for pain 
management. However, their use is contraindicated in 
women with GI ulcers, bronchial asthma. Side effects 
include nausea, vomiting, diarrhoea, abdominal pain, 
constipation, heart burn and dizziness. Other drugs 
include hormone therapy and calcium channel 
blockers. [11] 
To regulate uterine contractions and uterine 
tone, many effective Ayurvedic regimens are described 
in Ayurvedic classics and various studies have also 
been conducted; but a proper statistical analysis and 
interpretation are not available. Appropriate and 
validated parameters are lacking for assessment of 
efficacy of the drugs in some of these studies and 
sample size was also less to draw a conclusion. Further, 
health related quality of life has not assessed in any 
study. [12-15] 
Keeping this in view, this study was carried out 
on well known and safe classical Ayurvedic formulation 
Rajahpravartini vati that is being successfully 
prescribed by Ayurvedic physicians since centuries.  
OBJECTIVES 
The primary objective of this study was to 
establish the therapeutic usefulness of an Ayurvedic 
compound formulation- Rajahpravartini Vati in the 
management of primary dysmenorrhoea (DYS). The 
secondary objective was to assess the changes in the 
quality of life of the patients of DYS and to make 
ascertain the clinical safety of Rajahpravartini Vati.  
MATERIAL AND METHODS 
Study design 
This was a multi-centric prospective 
observational study. The patients were recruited 
between March, 2011 and August, 2012 from 09 
central and regional Institutes of Council for Research 
in Ayurvedic Sciences (CCRAS) viz. Ayurvedic Central 
Research Institute, Delhi, Nagpur and Jaipur; Ayurvedic 
Contraceptive Drug Research Institute, Ahmedabad; 
National Ayurvedic Dietetics Research Institute, 
Bengaluru; Dr. Achanta Laxmipati Research Centre for 
Ayurveda, Chennai; National Research Institute for 
Panchakarma, Cheruthuruthy; Ayurveda Regional 
Research Institute, Jammu and Ayurvedic Research 
Institute for Mother & Child health Care, 
Thiruvanantapuram.  
The study was approved by the Institutional 
Ethics Committee of each participating centre and 
complied with the Declaration of Helsinki and existing 
GCP guidelines of the country. All eligible subjects were 
screened after signing the informed consent form to the 
approved protocol prior to their enrollment in the 
study. All Investigators were trained in the protocol 
before initiation of the trial. The study has also been 
registered in Clinical Trial Registry of India, 
CTRI/2015/01/005429. 
Inclusion and Exclusion criteria 
The women aged between 16 to 35 years 
suffering from painful menstruation for at least three 
consecutive regular menstrual cycles (21 -35 days) 
having normal bleeding were included in the study. 
Patients of secondary dysmenorrhoea, abnormal 
reproductive system, pelvic inflammatory disease or 
any serious systemic disorders likely to influence the 
menstrual cycle, history of malignancy, hypo and 
hyperthyroidism, diabetes mellitus, hypertension, 
women using IUD/oral contraceptive pills, and 
participating in any other interventional study were 
excluded from the study. Pregnant and lactating 
women were also excluded. 
Study procedures 
At screening visit, subject’s demographic 
profile, medical history, family history particularly 
related to dysmenorrhoea, menstrual history, Prakriti 
(body constitution) and vital parameters were 
recorded. At each visit i.e.at baseline, 30th, 60th and 90th 
day (interventional period) study medication were 
dispensed and clinical assessment were performed. 
The clinical assessment and pain intensity also 
measured at 120th, 150th and 180th day (follow up 
period without intervention). 
Grading System 
The intensity of menstrual pain was measured 
in Visual Analogue Scale (VAS) using a 10 cm line 
represented the continuum of the opinion of the 
women on degree of pain. One end of the line ‘0’ 
represented ‘No pain’, and another end ‘10’ 
represented the ‘worst pain possible’.  
The scores received from the scale were classified into 
mild, moderate and severe as follows:[16] 
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Health related Quality of life (HRQoL) was 
recorded at baseline and end of the 90th day by using 
RAND 36 items Short Form health survey (SF-36) 
questionnaire. Safety lab assessments were also done 
at the end of the intervention period. 
 Patient compliance was monitored by keeping 
a regular follow up of the patients by personal contact, 
telephonic/ electronic communication. The 
investigators used to check the medicine packing for its 
exhaustion at each visit.  
Study population 
There was no procedure adopted for 
determination of sample size. However, a total of 368 
patients were enrolled in the study. 
Intervention 
Rajahpravartini vati (Figure-1) an Ayurvedic 
classical formulation was prepared as per the standard 
operative procedures mentioned in Ayurvedic 
Pharmacopoeia of India (API) and was tested for 
quality & safety parameters viz. heavy metal, aflatoxin, 
microbials & pesticide residue which was within limit. 
It was administered in a dose of 250 mg twice a day 
with lukewarm water for 90 days followed by 
subsequent 90 days without intervention.  
Outcome measures 
The primary outcome measure was changes in 
intensity of menstrual pain was assessed at baseline 
and every follow up i.e. 30th, 60th, 90th 120th, 150th and 
180th day by Visual Analogue Scale (VAS). The 
secondary outcome measure was HRQoL assessed at 
baseline and 90th day by using RAND (SF-36) 
questionnaire. It contains 36 items for assessment of 
eight health domains: physical functioning, social 
functioning, role limitations due to physical health, role 
limitations due to emotional health, vitality, mental 
health, bodily pain and general health perception and 
scores for each domain range from 0-100 with higher 
scores indicating better HRQoL. 
 
 
Statistical analysis 
Subjects who have taken the medicine at least 
in one follow up after the baseline were analyzed which 
included all patients with a baseline visit and at least 
one follow up visit. The data of last follow up visit was 
considered as the data of subsequent follow up visit up 
to the end of study period by ‘last observation carry 
forward method (LOCF)’ under modified intention-to-
treat analysis for missing data. The data of nine 
subjects was excluded from the analysis as they were 
reported at baseline only. Further, the data of those 
subjects who fulfilled the SF-36 (RAND) health survey 
questionnaire, both at baseline and end of the drug 
intervention period (90 days), was taken for analysis.  
The obtained data were entered and analyzed 
using the SPSS ver.15.0. Descriptive statistics e.g. 
frequencies and percentages for categorical variables; 
means and standard deviations (SD) for continuous 
variables were used to describe the total study cohort. 
Pair wise comparison and within subject effects of 
outcome measures were done by using repeated 
measures ANNOVA. Paired t-test was carried out for 
assessing the difference in health status (SF-36 health 
survey) from baseline to 90th day and demonstrated in 
a spider figure’. In all the analysis, p-values <0.05 were 
considered significant and p-values of the pair wise 
comparison were Bonferroni adjusted. McNemar’s Test 
was used to know improvement status of the outcome 
measures and the percentage of cure between the 
follow ups.  
RESULTS 
Total 477 subjects were screened according to 
the inclusion and exclusion criteria of the study 
protocol for participation in the study and a total of 368 
subjects were recruited. All vital parameters and lab 
safety parameters were performed within one week of 
the study initiation. The flow of the subjects through 
the study is shown in Figure-1. This paper reflects the 
analysis of 359 subjects including 36 subjects who 
dropped out from the study.  
 
 
 
 
 
 
 
 
 
Mild menstrual pain 1-3 points Menstruation is painful but seldom inhibits normal activity 
Moderate menstrual pain 4-7 points Daily activity is affected 
Severe menstrual pain 8-10 points Activity clearly inhibited with associated symptoms viz. headache, 
fatigue, vomiting, diarrhoea 
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Figure1: Showing flow of patients in the study
The base line characteristics of demographic 
information: the average age of the subjects was 22.0 ± 
(5.40) years (range 21-25 years), majority of subjects 
(62.1%) were students, 82.7 % were having education 
up to 10th or above. The menstrual pattern (amount 
and duration of menstrual flow and interval of cycle) 
was normal in all the subjects. 54.3% (n=159) subjects 
were having the family history of dysmenorrhoea. 
Majority of subjects 56.3% (n=202) were having Pittaj-
kaphaja Prakriti. The more detailed socio-economic 
and other characteristics of the subjects at baseline are 
shown in Table-1. 
Table 1: Baseline Characteristics of ITT population 
  Baseline population n (%) Mean  SD 
Total patients 359 (100)  
Age (in years) 
 Total 
 16-20 
 21-25 
  
359 (100) 
177 (49.3) 
101 (28.13) 
 
22.0 ± 5.40 
Educational status 
 Illiterate 
 Upto primary/middle 
 Upto 10th /college or above 
 Data not available 
 
11 (3.1) 
48 (13.4) 
297 (82.7) 
3 (0.8%) 
 
Marital status 
 Married 
 Unmarried 
 
91 (25.30) 
268 (74.70) 
 
Non-smoker & non-alcoholic 359 (100)  
Family history of Dysmenorrhoea 195 (54.3)  
Body weight (in kg)   49.14 ± 10.01 
Height (in cm)  154.33 ± 5.60 
BMI (kg/m2)  20.63 ± 4.06 
Body vitals 
 Pulse rate 
 Respiration rate 
Blood pressure (in mm Hg) 
 Systolic 
 Diastolic 
  
74.1 ± 5.4 
17.0 ± 1.9 
  
109.1 ± 8.3 
71.71 ± 7.7 
Prakriti (Predominant) 
 Pittaja-kaphaja 
 Vata-pittaja 
 
202 (56.3) 
87 (24.2) 
 
Excluded (n=109) 
 Not meeting inclusion criteria 
    - H/o hypo or hyper-thyroidism, abnormal 
thyroid profile- 48 
    - Abnormal USG findings (PCOD-30, 
fibroids-5, ovarian cysts-5, PID-3, 
Adenomyosis-3,  Hypo-plastic uterus-1, 
renal calculi-3)  
    - Abnormal laboratory findings (LFT, 
HbA1C)-5 
 
Assessed for eligibility (n=478) 
Enrolled (n=368) 
 
Total drop out (n=45) 
Lost to follow-up (n=42) (09 - After baseline  
    33 – 90th day) 
 
  Discontinued (n=03)        (After 30th, 90th and 
120th   day -Because 
of pregnancy during 
the trial) 
 
Completed  
n =323 
 
Analyzed (n=359) 
Excluded from analysis (n=09) as could 
not be contacted after baseline 
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Menstrual history 
 Age of menarche 
 Duration of menstrual flow 
 Amount of bleeding/day (in no. pads) 
 Length of menstrual cycle (in days) 
  
13.51 ± 1.18 
4.48 ± 1.1 
2.41 ± 0.74 
28.95 ± 3.3 
Outcome measures: 
Menstrual pain (in VAS)  
 Abdomen 
 Low back 
 Lower limbs 
Associated symptoms 
 Nausea 
 Vomiting 
 Constipation 
 Giddiness 
SF-36 (RAND) score 
 Physical functioning 
 Role Limitations due to physical health 
 Limitations due to emotional problem 
 Energy/Fatigue 
 Emotional well being 
 Social Functioning 
 Pain 
 
  
359(100) 
312 (86.9) 
 272(78.8) 
 
119 (33.1) 
76 (21.2) 
61 (17) 
88 (24.5) 
 
 
 
 
 
 
 
 
 
 
  
76.9 ± 26.8 
57.56 ± 42.84 
65.83 ± 41.01 
61.3 ± 19.8 
69.45 ± 18.01 
73.5 ± 22.2 
61.3 ± 21.4 
Lab safety parameters 
 Hemoglobin (g/dl) 
 Blood urea (mg/dl) 
 Serum creatinine mg/dl) 
 Serum Glutamic Oxaloacetic Transaminase (SGOT) (IU/L) 
 Serum Glutamic Pyruvic Transaminase (SGPT) (IU/L) 
 Serum Bilirubin Total (mg/dl) 
  
11.34 ± 1.6 
 17.6 ± 5.20 
0.70 ± 0.5 
20 ± 6.3 
18.6 ± 10.0 
0.53 ± 0.23 
ITT – Intention to treat; n - Number of subjects; SD - Standard Deviation 
Data are presented in mean± (SD) and number (%) 
Effects on symptoms and intensity of disease 
There was decreasing trend of mean VAS scores of pain in abdomen during menstrual cycle at each visit for 
the total study population. The mean VAS score at baseline was 6.94 SD (1.985), decreasing to 4.33 SD (2.63) at 30th 
day, 2.74 SD (2.47) at 60th day and 1.74 SD (2.22) at 90th day and further decreased and maintained to 1.24 SD 
(1.90) up to 180th day. The within group change from baseline was significant at all visits (p<0.001) (Wilcoxon 
signed rank test). The decrease from baseline at 90th day was 5.20 (95%Cl 4.78-5.62) and this was maintained 
during the post treatment period 5.68 (95%Cl 5.25-6.11) up to 180th day (Figure-2).  
 
 
Figure 2: Showing declination trend in pain score of dysmenorrhoic subjects
6.94
4.33
2.74
1.74
1.24 1.22 1.25
5.25
2.9
1.66
1.07
0.74 0.75 0.7
4.11
2.05
1.02
0.63
0.38 0.49 0.47
Baseline (0 day) 30th day 60th day 90th day 120th day 150th day 180th day
Pain in Abdomen (VAS) Mean Low Backache (VAS) Mean Pain in lower Limbs (VAS) Mean
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The subjects also got relief on the associated symptoms like nausea, vomiting, constipation, giddiness, 
breast tenderness, diarrhea, headache and fainting. The status of patients as relieved/ static/ worse at the end of 
the intervention and end of the observation period by using McNemar test is presented at Table-2. The data is 
showing statistically significant changes (p<0.001). 
Table 2: Overall effect of the trial drug on primary outcome measures 
Static (No change in score) depicts patients who were either asymptomatic or same as baseline. In McNemar test, 
only discordant cells are used for data analysis. Accordingly relieved (Complete reduction in score) and worsened 
(Increase in score from baseline) patients have been considered for analysis. 
Changes in health related quality of life  
The findings of this study shows that the score received on the various domains of SF-36 scales were 
improved at the end of 90th day and effect seen were also significant (p<0.001) (Figure-3). 
 
Figure 3: SF-36 (RAND) Health Survey domains 
All subjects tolerated the treatment well. None 
of the subjects developed any adverse drug reaction. 
There was no remarkable change in any of the safety 
lab parameters. 
DISCUSSION 
In this study, the effect of Rajahpravartini vati 
(Figure-4) on primary dysmenorrhoea has been 
evaluated. There was significant reduction in the 
menstrual pain and also improvement in the quality of 
life (physical as well as psychological) of the patients. 
The reduction of the pain was also stable during the 
follow up period without administering trial 
intervention. It proves the long lasting effect of the 
regimen. Some associated symptoms of primary 
dysmenorrhoea like nausea, vomiting, giddiness, 
constipation, diarrhea, fainting reported at baseline 
were almost completely reduced just after 30th day of 
the treatment. 
 
Figure 4: Rajahpravartini vati (tablet) 
0
20
40
60
80
100
Physical functioning
Role limitations due 
to physical health
Limitations due to 
emotional problems
Energy/Fatigue
Emotional well being
Social functioning
Pain
General Health
Baseline
At 90th  day
Variables After intervention period (90th day) (n,%) End of the period without intervention (n, %) 
Relieved Static Worse Chi 
square 
P 
value 
Relieved Static Worse Chi 
square 
P value 
Pain in 
abdomen 
137 (38.16) 222 (61.83) 0 135.08 <0.01 207 (57.66) 152 (42.33) 0 1.59 0.21 
Low 
Backache 
185 (51.67) 167 (46.64) 6 (1.6) 165.88 <0.01 223 (62.11) 133 (37.04) 3 (0.8) 0.09 0.76 
Pain in 
lower 
limbs 
199 (55.43) 155 (43.17) 5 (.01%) 182.59 <0.01 220 (61.28) 133 (37.04) 6 (1.67) 0.108 0.74 
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In Ayurvedic classics, drugs having 
carminative, laxative, anti-spasmodic properties are 
indicated in dysmenorrhoea and Rajahpravartini 
vati[17,18] seems to have all properties which help to 
cure dysmenorrhea. It contains purified Hingu (Ferula 
asafetida H.Kar.st), purified Kaseesa (Ferus sulphate), 
purified Tankana (borax) and Pulp of Aloe vera Linn. in 
equal quantity which is processed in Juice of Aloe vera. 
Hingu is reported to have antispasmodic activity. [19] In 
one study it was concluded that Aloe vera seems to 
reduce the severity of dysmenorrhea and can be a 
replacement to non-steroid anti-inflammatory tablets. 
[20] The mean age of the subjects was 22 years which 
also validate theory of the age of more prevalence of 
primary dysmenorrhoea. No adverse effects were 
reported during study period and no abnormalities 
were also found in the renal or liver functions. So, this 
Ayurvedic regimen appears clinically safe. Further, 
though it is not statistically significant as the patients 
were instructed not to try for pregnancy during the 
study period, it is observed that three women having 
the history of primary infertility got pregnancy during 
the treatment period. Further, study in this regard is 
suggested to prove its efficacy on infertility. 
There were some limitations in this study. 
Though the consumption of analgesic was reduced/ not 
required during the study period but the specific data 
could not be reported due to inadequate information 
from the subjects. Further, no comparator group was 
taken to compare the efficacy of trial drug and 
prostaglandin was not assessed to know the 
mechanism of the action of the drug. In future study, 
these points may be taken into account. 
CONCLUSION 
This study has provided a clear cut support for 
clinical use of Rajahpravartini vati to treat primary 
dysmenorrhoea and clinically meaningful improvement 
of quality of life of the dysmenorrhoic women. 
However, because of the open label and non-
comparative nature of the present study, the findings 
may further be corroborated through a randomized, 
controlled study.  
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